Krystal Biotech
KRYS
113 hedge funds and large institutions have $851M invested in Krystal Biotech in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 44 increasing their positions, 34 reducing their positions, and 10 closing their positions.
60% more call options, than puts
Call options by funds: $35.8M | Put options by funds: $22.3M
29% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 34
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
0% more funds holding
Funds holding: 113 → 113 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.51% less ownership
Funds ownership: 73.86% → 73.36% (-0.51%)
24% less capital invested
Capital invested by funds: $1.12B → $851M (-$265M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.96M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.32M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.29M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$12M |
| 2 |
JP Morgan Chase
New York
|
-$11M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.61M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7.37M |
| 5 |
Goldman Sachs
New York
|
-$6.78M |
KRYS Hedge Fund Activity: Q3 2021 in Review
113 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2021, worth a combined $851M — down 24% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KRYS positions and 10 closed out — a net gain of 2 holders — while 44 added to existing stakes and 34 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $11.5M. The largest seller was Fidelity International, exiting entirely with an estimated $12M sold.
- 113 institutional investors held Krystal Biotech (KRYS) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $851M of Krystal Biotech stock for Q3 2021, down 24% quarter-over-quarter.
- 12 funds opened new Krystal Biotech positions in Q3 2021 and 10 closed out, a net change of +2 holders.
- The largest Krystal Biotech buyer in Q3 2021 was Point72 Asset Management, an estimated $11.5M added.
- The largest Krystal Biotech seller in Q3 2021 was Fidelity International, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2021.